[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ruptured-intracranial-aneurysms\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ruptured-intracranial-aneurysms":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":4},"100655899","phase-3-the-efficacy-and-safety-of-tirofiban-enhanced-antiplatelet-therapy-in-the-treatment-of-ruptured-intracranial-aneurysms-with-stent-100655899",false,"NCT07818083","The Efficacy and Safety of Tirofiban Enhanced Antiplatelet Therapy in the Treatment of Ruptured Intracranial Aneurysms With Stent","The Efficacy and Safety of Tirofiban Enhanced Antiplatelet Therapy in the Treatment of Ruptured Intracranial Aneurysms With Stent (TEARIAS): A Multicenter, Open-Label, Single-Blind, Randomized Controlled Trial","TEARIAS","Inclusion Criteria:\n\n* Age 18-75 years; Acute subarachnoid hemorrhage confirmed by head CT, with a WFNS grade of 1-4; DSA-confirmed aneurysmal SAH treated with successful stent deployment; Surgical intervention performed within 72 hours after symptom onset.\n\nExclusion Criteria:\n\n* Blood blister-like aneurysms or recurrent aneurysms; Abnormal coagulation profiles (INR \\>1.5 or platelet count \\\u003C100 × 10⁹\u002FL); Pregnancy, peripartum status, or lactation; Secondary aneurysm rupture due to infection, trauma, tumor invasion, vascular malformation, moyamoya disease, or other pathological causes; Concomitant intracranial hemorrhage; Hypersensitivity to amikacin, ceftriaxone, or related drugs; Autoimmune diseases (e.g., systemic lupus erythematosus); Severe comorbidities, life expectancy ≤3 months, or other investigator-determined reasons precluding enrollment.","ALL","18 Years","75 Years",{"count":21,"type":22},622,"ESTIMATED","INTERVENTIONAL",[25],"PHASE3","This multicenter prospective randomized controlled study will enroll patients with ruptured intracranial aneurysms receiving stent-assisted coiling across multiple Chinese medical centers. The investigators aim to evaluate the efficacy and safety of tirofiban-enhanced antiplatelet therapy versus conventional dual antiplatelet treatment on the 90-day neurological prognosis and major adverse cerebrovascular events of enrolled subjects.",[28,29],"Ruptured Intracranial Aneurysms","Subarachnoid Hemorrhage, Aneurysmal",[31,28,32,33],"Subarachnoid Hemorrhage","Tirofiban","Dual Antiplatelet Therapy","NOT_YET_RECRUITING","2026-09-09",{"date":37,"type":38},"2026-09-14","ACTUAL",{"date":40,"type":22},"2026-09-01",{"date":42,"type":22},"2028-12-31",{"name":44,"class":45},"First Affiliated Hospital of Fujian Medical University","OTHER"]